Colleen Kusy
Stock Analyst at Baird
(1.20)
# 2,631
Out of 4,415 analysts
22
Total ratings
36.36%
Success rate
-11.31%
Average return
Main Sectors:
Top Industries:
12 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Initiates: Outperform | $50 | $33.87 | +47.62% | 1 | May 2, 2024 | |
| OCS Oculis Holding AG | Maintains: Outperform | $64 → $35 | $12.85 | +172.37% | 2 | Mar 19, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $9.33 | +167.95% | 1 | Mar 12, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $1 → $5 | $3.37 | +48.37% | 3 | Feb 29, 2024 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $70.65 | +48.62% | 1 | Feb 23, 2024 | |
| APLS Apellis Pharmaceuticals | Reiterates: Outperform | $81 | $46.05 | +75.90% | 4 | Feb 6, 2024 | |
| CHRS Coherus BioSciences | Maintains: Outperform | $11 → $9 | $2.06 | +336.89% | 2 | Jan 23, 2024 | |
| OCUL Ocular Therapeutix | Reiterates: Outperform | $18 | $5.02 | +258.57% | 3 | Sep 14, 2023 | |
| AGEN Agenus | Initiates: Outperform | $160 | $13.26 | +1,106.64% | 1 | Jun 6, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $17 → $14 | $1.08 | +1,196.30% | 1 | Aug 5, 2022 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $34 | $12.50 | +172.00% | 2 | Apr 7, 2022 | |
| SABS SAB Biotherapeutics | Initiates: Outperform | $230 | $4.10 | +5,509.76% | 1 | Nov 2, 2021 |
Spyre Therapeutics
May 2, 2024
Initiates: Outperform
Price Target: $50
Current: $33.87
Upside: +47.62%
Oculis Holding AG
Mar 19, 2024
Maintains: Outperform
Price Target: $64 → $35
Current: $12.85
Upside: +172.37%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $9.33
Upside: +167.95%
Mersana Therapeutics
Feb 29, 2024
Maintains: Neutral
Price Target: $1 → $5
Current: $3.37
Upside: +48.37%
Nuvalent
Feb 23, 2024
Initiates: Outperform
Price Target: $105
Current: $70.65
Upside: +48.62%
Apellis Pharmaceuticals
Feb 6, 2024
Reiterates: Outperform
Price Target: $81
Current: $46.05
Upside: +75.90%
Coherus BioSciences
Jan 23, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $2.06
Upside: +336.89%
Ocular Therapeutix
Sep 14, 2023
Reiterates: Outperform
Price Target: $18
Current: $5.02
Upside: +258.57%
Agenus
Jun 6, 2023
Initiates: Outperform
Price Target: $160
Current: $13.26
Upside: +1,106.64%
Karyopharm Therapeutics
Aug 5, 2022
Maintains: Outperform
Price Target: $17 → $14
Current: $1.08
Upside: +1,196.30%
Iovance Biotherapeutics
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $12.50
Upside: +172.00%
SAB Biotherapeutics
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $4.10
Upside: +5,509.76%